Haleon PLC Sponsored ADR (HLN) AI Stock Analysis

• Market Cap: $41.49B
• Dividend Yield: 1.86%
• Average Volume (3M): 9.38M
• Price to Earnings (P/E): 21.4
• Beta (1Y): 0.19
• Revenue Growth: 0.58%
• EPS Growth: 45.74%
• Country: US
• Employees: 24,561
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.24
• Shares Outstanding: 4,453,211,400
• 10 Day Avg. Volume: 10,220,639
• 30 Day Avg. Volume: 9,384,226
• PEG Ratio: 0.72
• Price to Book (P/B): 2.15
• Price to Sales (P/S): 3.10
• P/FCF Ratio: 16.97
• Enterprise Value/Market Cap: 1.39
• Enterprise Value/Revenue: 10.54
• Enterprise Value/Gross Profit: 16.34
• Enterprise Value/Ebitda: 41.47
• 1Y Price Target: $13.44
• Price Target Upside: 41.18% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 67 Neutral
• Price Target: $10.00 ▲(5.04% Upside)

Haleon PLC's overall stock score reflects a strong financial foundation with robust cash flow and profitability metrics, but tempered by flat revenue growth and challenges in the North American market. The technical indicators suggest a neutral trend, and the valuation is moderate. The earnings call provided a balanced view of strengths in international markets and challenges in North America.

Positive Factors

Cash Flow Generation

Efficient cash conversion supports long-term sustainability and growth opportunities, indicating robust financial health.

International Market Growth

Strong performance in international markets suggests successful geographic expansion and potential for sustained revenue growth.

Salesforce Partnership

The partnership with Salesforce enhances customer engagement capabilities, potentially improving sales effectiveness and market reach.

Negative Factors

North America Sales Decline

Declining sales in North America could indicate market saturation or competitive pressures, impacting overall revenue growth.

Smokers' Health Category Decline

Declines in the Smokers' Health category suggest challenges in product demand, potentially affecting long-term segment performance.

Challenges with Centrum and Advil

Struggles with key brands like Centrum and Advil may hinder market share growth and brand positioning in a competitive landscape.

Haleon PLC Sponsored ADR Business Overview & Revenue Model

Company Description

Haleon PLC Sponsored ADR (HLN) is a global consumer healthcare company dedicated to delivering everyday health products that enhance the well-being of consumers around the world. Established as a standalone entity, Haleon focuses on over-the-counter medications, oral health, dietary supplements, and wellness products. The company operates in segments such as oral care, pain relief, respiratory health, and vitamins and supplements, offering well-known brands that are trusted by consumers, including Sensodyne, Panadol, and Centrum.

How the Company Makes Money

Haleon generates revenue primarily through the sale of consumer healthcare products across its various segments. The company's revenue model is built on a combination of direct sales to retailers, wholesalers, and e-commerce platforms, as well as through partnerships with pharmacies and other healthcare providers. Key revenue streams include over-the-counter medications, oral health products, and dietary supplements, which are sold globally. Haleon benefits from strong brand recognition and loyalty, which drive repeat purchases. Additionally, the company invests in marketing and innovation to expand its product offerings and reach new consumer segments, further contributing to its earnings.

Haleon PLC Sponsored ADR Financial Statement Overview

Summary

Haleon PLC shows a strong financial position with stable profitability margins and efficient cash flow generation. While revenue growth has been flat, the company maintains a solid balance sheet with a balanced debt profile and sufficient equity. The cash flow metrics are particularly robust, supporting long-term sustainability and potential growth opportunities.

Income Statement

The company showcases strong profitability with a consistent gross profit margin around 61.9% in the latest year. The net profit margin improved to 12.8% from the previous year's 9.3%, indicating an enhanced bottom line. EBIT and EBITDA margins are robust at 19.6% and 22.4%, respectively. However, revenue growth has stagnated, with a slight decrease from the previous year, reflecting potential challenges in expanding market share.

Balance Sheet

The balance sheet reflects a moderate debt-to-equity ratio of 0.64, highlighting a balanced approach to leveraging. Return on equity stands at 8.9%, showing decent profitability relative to shareholder investment, though slightly lower than industry leaders. The equity ratio is strong at 47.1%, indicating a solid capital structure with substantial equity backing the assets.

Cash Flow

Cash flow generation is strong with an operating cash flow to net income ratio of 1.6, indicating efficient cash conversion from profits. Free cash flow to net income ratio is 1.4, demonstrating healthy free cash flow generation. The free cash flow growth rate of 16.3% over the previous year highlights effective cash management and capital efficiency.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	5.48B	11.23B	11.30B	10.86B	9.54B	9.89B
Gross Profit	3.54B	6.95B	6.96B	6.58B	5.95B	5.91B
EBITDA	1.39B	2.51B	2.35B	2.18B	2.21B	1.91B
Net Income	806.00M	1.44B	1.05B	1.06B	1.39B	1.15B
Balance Sheet
Total Assets	31.83B	34.31B	34.05B	34.81B	34.45B	34.13B
Cash, Cash Equivalents and Short-Term Investments	676.00M	2.25B	1.04B	684.00M	414.00M	334.00M
Total Debt	8.45B	10.10B	9.46B	10.44B	991.00M	487.00M
Total Liabilities	15.83B	18.09B	17.33B	18.36B	7.97B	7.91B
Stockholders Equity	15.94B	16.17B	16.61B	16.33B	26.36B	26.11B
Cash Flow
Free Cash Flow	931.00M	2.05B	1.76B	1.74B	1.06B	1.09B
Operating Cash Flow	1.03B	2.30B	2.10B	2.06B	1.36B	1.41B
Investing Cash Flow	-76.00M	528.00M	-134.00M	-8.78B	-33.00M	1.03B
Financing Cash Flow	-2.52B	-1.54B	-1.57B	6.91B	-1.24B	-2.44B

Haleon PLC Sponsored ADR Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 9.52
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HLN, the sentiment is Neutral. The current price of 9.52 is below the 20-day moving average (MA) of 9.61, above the 50-day MA of 9.41, and below the 200-day MA of 9.87, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 49.29 is Neutral, neither overbought nor oversold. The STOCH value of 39.41 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HLN.

Haleon PLC Sponsored ADR Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RDY	73 Outperform	$11.56B	16.96	17.72%	0.66%	10.63%	6.35%
HLN	67 Neutral	$41.49B	21.43	9.20%	1.86%	0.58%	45.74%
TEVA	63 Neutral	$33.58B	49.29	10.77%	―	-0.25%	―
TAK	63 Neutral	$45.65B	170.46	0.54%	4.15%	-1.98%	-86.20%
VTRS	60 Neutral	$12.89B	―	-21.09%	4.14%	-6.40%	-320.23%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
PRGO	49 Neutral	$1.85B	-35.68	-0.65%	8.64%	-2.55%	66.00%

Haleon PLC Sponsored ADR Corporate Events

Haleon PLC Executes Share Buyback Program

On September 12, 2025, Haleon PLC announced the purchase and cancellation of 273,737 ordinary shares as part of the second tranche of its share buyback program initiated on July 31, 2025. This transaction is expected to impact the company’s share capital and voting rights, with the current number of ordinary shares with voting rights standing at 8,950,849,678. This strategic move is likely to influence Haleon’s market positioning and shareholder interests, aligning with the company’s ongoing financial strategies.

Haleon PLC Executes Share Buyback of 172,878 Shares

On September 11, 2025, Haleon PLC announced the purchase of 172,878 ordinary shares for cancellation as part of the second tranche of its share buyback program initiated on July 31, 2025. This transaction reflects Haleon’s strategic efforts to manage its capital structure and potentially enhance shareholder value, impacting the company’s share capital and voting rights.

Haleon PLC Discloses PDMR Share Transactions

On September 10, 2025, Haleon PLC announced a notification and public disclosure regarding transactions by Persons Discharging Managerial Responsibilities (PDMRs) under the UK Market Abuse Regulation. The transactions involved the acquisition of Partnership Shares and the award of Matching Shares under the company’s Share Reward Plan by Adrian Morris, General Counsel, and Tamara Rogers, Chief Marketing Officer, on September 9, 2025, at the London Stock Exchange. This disclosure highlights Haleon’s commitment to transparency and regulatory compliance, potentially impacting stakeholder confidence and market perception.

Haleon PLC Advances Share Buyback Program with Recent Share Purchase

On September 10, 2025, Haleon PLC announced the purchase of 1,590,000 ordinary shares for cancellation as part of the second tranche of its share buyback program initiated on July 31, 2025. This transaction, conducted on September 9, 2025, aims to optimize the company’s capital structure and potentially enhance shareholder value by reducing the number of shares with voting rights to 8,951,243,846. This strategic move may strengthen Haleon’s market position and reflect positively on its commitment to returning value to its shareholders.

Haleon PLC Executes Share Buyback of 1.2 Million Shares

On September 9, 2025, Haleon PLC announced the purchase of 1,200,000 ordinary shares for cancellation as part of the second tranche of its share buyback program initiated on July 31, 2025. This move is likely to impact the company’s share capital and voting rights, with the current number of ordinary shares with voting rights standing at 8,952,833,846. The buyback reflects Haleon’s strategic efforts to manage its capital structure and could influence shareholder value positively.